Genetic Disorder Tracker introduced by Guidepoint Global

Guidepoint Global, LLC, a leading primary research firm, today announced the launch of their Genetic Disorder Tracker, a monthly longitudinal data release that captures commercial trends, on a worldwide basis, associated with the treatment of eight rare genetic disorders: Gaucher's disease, Fabry's disease, PKU, MPS I (Hurler Syndrome), MPS II (Hunter Syndrome), MPS VI (Maroteaux-Lamy Syndrome), Niemann-Pick disease and Pompe disease.

Guidepoint's Genetic Disorder Tracker aggregates the utilization of more than 10 therapies reported by a clinical sample comprised of more than 100 worldwide sites in over 20 countries.  Key commercial metrics covered by the Guidepoint Genetic Disorder Tracker include treatment volume, market share, drug penetration rates, therapy switching, patient activity and the geographically-stratified performance of leading company participants including Genzyme (GENZ), Shire (SHP), BioMarin (BMRN), Merck Serono, Actelion (ATLN), Pfizer (PFE) and Protalix (PLX), among others.

"Despite being a broad product area with over $2 billion in annual sales, it has been nearly impossible to systematically track the genetic disorder market, especially on a global basis," said Maxim Jacobs, Senior Analyst at Guidepoint Global. "This need has become even more acute with the recent supply disruptions in Gaucher's and Fabry's as well as the upcoming new product launches.  Guidepoint Global's new Genetic Disorder Tracker will provide followers of the genetic disorder market with a much needed tool to analyze the market and identify meaningful changes in the size and character of the commercial landscape."

The Genetic Disorder Tracker is the 28th Tracker developed by Guidepoint Global. The firm's Tracker offerings, a collection of novel research products that monitor usage trends and market share in select medical technology and therapeutic industries, deliver timely, accurate insight in a broad range of inefficiently-covered healthcare product areas in over 50 countries.

An overview of Guidepoint Global's proprietary suite of Tracker offerings is available at

SOURCE Guidepoint Global, LLC


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
What is the difference in risk of early prostate cancer death between men at higher vs lower genetic risk?